Trial Profile
Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 Feb 2021
Price :
$35
*
At a glance
- Drugs Oprozomib (Primary)
- Indications Haematological malignancies; Multiple myeloma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 17 Feb 2021 Status changed from completed to discontinued. Reason the study was stopped: A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted.
- 13 Aug 2019 Status changed from active, no longer recruiting to completed.
- 31 Jul 2019 Planned End Date changed from 29 Jul 2019 to 12 Aug 2019.